# Risankizumab Intravenous Infusion for Adults

## Who can administer

May be administered by registered competent doctor or nurse/midwife

## Important information

- Consider premedication (antihistamine and/or paracetamol) if infusion-related reactions are anticipated [(ref 1)]
- In order to improve the traceability of biological medicinal products,Â **the name and the batch number of the administered product should be clearly recorded**
- Confirm patient doesÂ **not have a history of current or recent infection**, or recent exposure to chicken pox or TB
- **Immunisations**
    - Prior to initiating therapy with risankizumab, completion of all appropriate immunisations should be considered according to current immunisation guidelines
    - If a patient has received live vaccination (viral or bacterial), it is recommended to wait at least 4 weeks prior to starting treatment with risankizumab
    - Patients treated with risankizumab should not receive live vaccines during treatment and for at least 21 weeks after treatment

## Available preparations

Skyrizi 600 mg per 10mL vial

## Reconstitution

Already in solution

**Dilute further prior to administration**

## Infusion fluids

Sodium chloride 0.9% or Glucose 5%

## Methods of intravenous administration

**Intermittent intravenous infusion (using an electronically controlled infusion device)**

- This is a monoclonal antibody. Reduce direct handling to a minimum and wear appropriate

personal protective equipment. [ref 1]

- **Prepare and administer according to the following table**

| Indication | Intravenous induction dose | Number of 600mg/10mL vials | Volume of infusion fluid | Infusion duration |
|---|---|---|---|---|
| **Crohn's disease** | 600mg | 1 | 100, 250 or 500mL | at least 60 minutes |
| **Ulcerative colitis** | 1200mg | 2 | 250 or 500mL | at least 120 minutes |

**Do not shake the solution in the vial or in the infusion bag** **Â**

# Dose in adults

**Crohn's disease**

- Give 600mg at week 0,4 and 8
- Change to subcutaneous injection thereafter - see manufacturer's instructions for doses

Â **Ulcerative colitis**

- Give 1200mg at week 0,4 and 8
- Change to subcutaneous injection thereafter - see manufacturer's instructions for doses

**Renal or hepatic impairment**

- No dose adjustment required

# Storage

Store between 2 and 8$^{0}$C

# References

SPC July 2024

1: Injectable medicines guide, Medusa, Downloaded Oct 2024

# Therapeutic classification

Immunosuppressant, interleukin inhibitor